Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15203067 | 0.80 | PGK1 (0.45) | CAPN1 | |
| SCHEMBL15855460 | 0.80 | CA2 (0.41) | BLMSRCSMN1; SMN2GRB2CAPN1 | |
| SCHEMBL25660764 | 0.80 | LDHA (0.50) | CYP2C19SMN1; SMN2 | |
| SCHEMBL20353307 | 0.78 | ESR1 (0.42) | — | |
| SCHEMBL18362262 | 0.77 | ANPEP (0.45) | BLMSRCCYP2C19SMN1; SMN2GRB2 | |
| SCHEMBL18403599 | 0.77 | NQO1 (0.45) | — | |
| SCHEMBL14490963 | 0.77 | SRC (0.47) | BLMSRCGRB2ZAP70 | |
| SCHEMBL15315066 | 0.77 | SRC (0.47) | BLMSRCGRB2ZAP70 | |
| SCHEMBL16684116 | 0.77 | SRC (0.47) | BLMSRCGRB2ZAP70CA2 | |
| SCHEMBL9630785 | 0.76 | TAAR1 (0.46) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3769776-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2822572-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2016154058-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016049355-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049359-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2015157508-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2014138429-A2 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013123266-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |